Evidence map›Paper›PMID 38806739›Full record

ArticleWorld journal of urology2024

Comparison of ciprofloxacin versus fosfomycin versus fosfomycin plus trimethoprim/sulfamethoxazole for preventing infections after transrectal prostate biopsy.

Alberto Bovo, Maciej Kwiatkowski, Lukas Manka, Christian Wetterauer, Christoph Andreas Fux, Marco Cattaneo, Stephen F Wyler, Lukas Prause

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Alberto Bovo *Department of Urology, Cantonal Hospital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. alberto.bovo@ksa.ch.
Maciej Kwiatkowski *Department of Urology, Cantonal Hospital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.
Lukas MankaDepartment of Urology, Academic Hospital Braunschweig, Brunswick, Germany.
Christian WetterauerMedical Faculty, University Hospital Basel, Basel, Switzerland.
Christoph Andreas FuxDepartment of Infectious Diseases and Hospital Hygiene, Cantonal Hospital Aarau, Aarau, Switzerland.
Marco CattaneoDepartment of Clinical Research, University of Basel, 4001, Basel, Switzerland.
Stephen F WylerDepartment of Urology, Cantonal Hospital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.
Lukas PrauseDepartment of Urology, Cantonal Hospital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate antibiotic prophylaxis in transrectal prostate biopsies due to the recommendation of the European Medicines Agency (EMA): We describe our single center experience switching from ciprofloxacin to fosfomycin trometamol (FMT) alone and to an augmented prophylaxis combining fosfomycin and trimethoprim/sulfamethoxazole (TMP/SMX).

methodsBetween 01/2019 and 12/2020 we compared three different regimes. The primary endpoint was the clinical diagnosis of an infection within 4 weeks after biopsy. We enrolled 822 men, 398 (48%) of whom received ciprofloxacin (group-C), 136 (16.5%) received FMT (group-F) and 288 (35%) received the combination of TMP/SMX and FMT (group-BF).

resultsBaseline characteristics were similar between groups. In total 37/398 (5%) postinterventional infections were detected, of which 13/398 (3%) vs 18/136 (13.2%) vs 6/288 (2.1%) were detected in group-C, group-F and group-BF respectively. The relative risk of infectious complication was 1.3 (CI 0.7-2.6) for group-C vs. group-BF and 2.8 (CI 1.4-5.7) for group-F vs. group-BF respectively.

conclusionThe replacement of ciprofloxacin by fosfomycin alone resulted in a significant increase of postinterventional infections, while the combination of FMT and TMP/SMX had a comparable infection rate to FQ without apparent adverse events. Therefore, this combined regimen of FMT and TMP/SMX is recommended.

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisCiprofloxacinDrug Therapy, CombinationFosfomycinProstateTrimethoprim, Sulfamethoxazole Drug CombinationAgedBiopsyHumansMaleMiddle AgedPostoperative ComplicationsRectumRetrospective StudiesAnti-Bacterial AgentsCiprofloxacinFosfomycinTrimethoprim, Sulfamethoxazole Drug CombinationAntibiotic prophylaxisPeriinterventional prophylaxisProstate biopsyProstate cancer

Identifiers

PMID38806739
PMCPMC11133158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.